Effect of brimonidine tartrate gel 0.33% versus tretinoin cream 0.05% on post-acne erythema

Effect of brimonidine tartrate gel 0.33% versus tretinoin cream 0.05% on post-acne erythema: a single-blind randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N490

Enrollment

Registered

2023-11-19

Start date

2023-12-06

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne. Acne

Interventions

Intervention 1: Intervention group: Brimonidine tartrate gel 0.33% once a day topically at the site of acne erythema for 4 weeks. Intervention 2: Control group: Tretinoin cream 0.05% once a day topica

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Age 18 to 70 years Erythema after acne

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding Taking anti-acne drugs in the last 3 months Contraindications to Brimonirin (including treatment failure, brain failure, depression, blood pressure, scleroderma, Sjogren's syndrome, Raynaud's phenomenon)

Design outcomes

Primary

Measure	Time frame
Severity of post-acne erythema. Timepoint: Before the intervention and in the fourth and eighth weeks after the intervention. Method of measurement: By clinical examination.	—

Secondary

Measure	Time frame
Skin burning. Timepoint: In the fourth and eighth weeks after the intervention. Method of measurement: By taking a history.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Roshanak Kazemirad

Hamedan University of Medical Sciences

Karadr26@gmail.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026